Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026)
Anaptysbio (ANAB) reported Return on Capital Employed of 13.36% for Q1 2026, up 1723.0% on a YoY basis from 0.73% in Q1 2025, and down 10.7% quarter-over-quarter from 14.96% in Q4 2025.
Anaptysbio (ANAB) Return on Capital Employed (2017 - 2026) Analysis & Trends
Anaptysbio has reported Return on Capital Employed for 10 years, with the latest figure at 13.36% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 1723.0% year-over-year to 13.36%; the trailing twelve-month figure through Mar 2026 stood at 13.36% (up 1723.0% YoY), and the FY2025 full-year result was 12.42%, up 1964.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 13.36%, down from 14.96% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.22% in Q3 2025, with the low at 32.02% in Q3 2023.
- Historically, Return on Capital Employed has averaged 8.54% across 5 years, with a median of 8.1% in 2024.
- Annual changes were most pronounced in 2022 — Return on Capital Employed slumped 2229 bps — and 2024, when it surged 2785 bps.
- Anaptysbio's Return on Capital Employed stood at 19.57% in 2022, then jumped by 59 bps to 7.95% in 2023, then increased by 13 bps to 6.88% in 2024, then surged by 317 bps to 14.96% in 2025, then declined by 11 bps to 13.36% in 2026.
- The last three Return on Capital Employed figures came in at 13.36% (Q1 2026), 14.96% (Q4 2025), and 18.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Anaptysbio | 1.66 Bn | 1.38 Bn | - | 13.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.36% |
| Dec 31, 2025 | 14.96% |
| Sep 30, 2025 | 18.22% |
| Jun 30, 2025 | -0.49% |
| Mar 31, 2025 | -3.87% |
| Dec 31, 2024 | -6.88% |
| Sep 30, 2024 | -4.17% |
| Jun 30, 2024 | -8.60% |
| Mar 31, 2024 | -8.10% |
| Dec 31, 2023 | -7.95% |
| Sep 30, 2023 | -32.02% |
| Jun 30, 2023 | -28.44% |
| Mar 31, 2023 | -23.44% |
| Dec 31, 2022 | -19.57% |
| Sep 30, 2022 | -20.39% |
| Jun 30, 2022 | -16.39% |
| Mar 31, 2022 | -11.43% |
| Dec 31, 2021 | -10.98% |
| Sep 30, 2021 | 1.90% |
| Jun 30, 2021 | -2.53% |